ArticleCancer reports (Hoboken, N.J.)2026
Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin rash (SR) is a key issue in the long-term use of apalutamide (APA) in patients with prostate cancer (PCa); however, there is currently no established strategy for the safe management of APA in preventing SR.
aimsTo investigate the predictive value of early elevation in the proportion of eosinophils (EE) for SR in patients treated with APA for PCa. METHODS AND
resultsWe retrospectively reviewed the clinical data of 78 patients who received APA for PCa between April 2021 and November 2024. Early EE was defined as beyond the upper normal limit of 5.0% within 3 months of APA treatment initiation. The initial SR (I-SR) and recurrent (R-) SR incidences were compared between patients with and without early EE. During a median follow-up period of 14.7 months, 35 patients (44.9%) developed SR, and a significantly higher proportion of patients with early EE had I-SR than those without early EE (87.5% [7/8] vs. 40.0% [28/70]; p = 0.020). Six of the seven patients with early EE and I-SR had EE before the onset of I-SR (85.7%). In terms of R-SR, among patients who reduced the APA dose after I-SR, R-SR remained significantly more prevalent in patients with early EE compared with that in patients without early EE (75.0% [3/4] vs. 11.1% [2/18]; p = 0.016).
conclusionThe present study suggests that early EE has predictive value for I- and R-SR in patients who receive APA for PCa. Further large-scale studies are warranted to verify the clinical utility of early EE in patients with APA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.